Market Overview - The U.S. stock market showed mixed results on August 19, with the Dow Jones up by 0.64%, while the S&P 500 and Nasdaq fell by 0.01% and 0.66% respectively [1] Federal Reserve and Economic Outlook - Investors are awaiting Federal Reserve Chairman Jerome Powell's speech at the upcoming global central bank conference, focusing on the theme of "Labor Market Transformation: Demographics, Productivity, and Macroeconomic Policy" [3] - Powell faces a challenging economic situation with signs of a cooling labor market and rising inflation due to tariff policies, complicating interest rate decisions [3] - There is an 83% probability that the Federal Reserve will cut rates by 25 basis points in September, according to the FedWatch tool [3] Intel's Stock Surge - Intel's stock surged by nearly 12% after receiving significant investments from the Trump administration and SoftBank Group, with the stock still up over 8% at the time of reporting [4] - The Trump administration is expected to acquire approximately 10% of Intel's shares, potentially providing around $10 billion to support Intel's revival strategy [4] - SoftBank Group plans to invest $2 billion in Intel, aiming to leverage Intel's chip manufacturing technology for artificial intelligence applications [4] Viking Therapeutics' Stock Plunge - Viking Therapeutics' stock plummeted over 41% due to disappointing mid-stage trial data for its experimental oral weight loss drug [5] - The drug VK2735 showed a maximum weight loss of 12.2%, but 28% of participants dropped out of the trial within three months, undermining confidence in its competitiveness against products from Eli Lilly and Novo Nordisk [6] - Other pharmaceutical companies have also faced stock declines due to underwhelming results from weight loss drug trials, highlighting the significant scientific challenges in this emerging field [6]

and the obesity pill race. Mizuo healthcare strategist Jared Holtz joins us here on the set. You know, beyond just the patients being nauseous, investors are too today, down 42%.Is this it. I mean, are they done. Is Viking Therapeutics out of this race for the obesity pill.>> I don't think they're done. I mean, it's a it's a big setback for sure. It's going to come down to what the next trial looks like, what the dosing is, but this sort of discontinuation rate when you have monster companies that are ahead ...

More on this. Our next guest today says today's reaction is overdone. That Vikings data is comparable or maybe even a bit better than Nova Nordisks and Eli Liys.He's sticking with a buy rating and a $125 price target. Joining me now is Justin Zelen. He's the biotech analyst at BTIG.All right, Justin, make your case. Why shouldn't investors abandon the stock as apparently so many of them are today. >> Thanks for having me on, David.Appreciate it. Yeah, I I I I have to say I think that the market reaction her ...

Company Overview - Proactive is a publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive delivers news and insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking and enthusiastic adopter of technology, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Viking's new GLP-1 weight loss pill is pretty great -- but is it enough to turn the company profitable? Is Viking Therapeutics stock a buy? Viking and VK2735 Don't get me wrong: A weight loss pill that requires no injections or needles and helps people lose nearly 1% of their body weight in a week sounds pretty great. It just may not mean that Viking has come up with a wonder drug to beat all other wonder drugs. In a press release this morning, Viking put a brave face on results of its "Phase 2 VENTURE-Oral ...

Market Overview - The U.S. stock market showed mixed results with the Dow Jones up by 0.64%, while the S&P 500 and Nasdaq fell by 0.01% and 0.66% respectively as investors await Federal Reserve Chairman Jerome Powell's speech at the global central bank conference [1][3]. Federal Reserve Insights - The upcoming Jackson Hole conference from August 21 to 23 focuses on "Labor Market Transformation: Demographics, Productivity, and Macroeconomic Policy," reflecting recent significant changes in the U.S. labor market [3]. - Powell faces a challenging economic situation with signs of a cooling labor market indicating potential economic slowdown, while tariffs from the Trump administration are exacerbating inflation, complicating interest rate decisions [3]. - Market expectations suggest an 83% probability of a 25 basis point rate cut in September, with Powell likely to emphasize the Fed's independence from the administration during his final Jackson Hole appearance [3]. Intel's Stock Surge - Intel's stock price surged by nearly 12% after receiving substantial investments from the Trump administration and SoftBank Group, ultimately rising over 8% [5]. - The Trump administration is expected to acquire approximately 10% of Intel's shares, potentially providing around $10 billion to support Intel's revival strategy led by CEO Pat Gelsinger [7]. - SoftBank Group has agreed to purchase $2 billion in Intel shares, aiming to leverage Intel's chip manufacturing technology for artificial intelligence applications, while also increasing its stake in Nvidia [8]. Viking Therapeutics' Stock Decline - Viking Therapeutics' stock plummeted over 41% following disappointing mid-stage trial results for its experimental oral weight loss drug, VK2735, which showed only a 12.2% weight reduction in patients [10]. - Approximately 28% of participants dropped out of the trial within three months, raising concerns about the drug's competitiveness against products from Eli Lilly and Novo Nordisk [10]. - Other pharmaceutical companies have also faced stock declines due to underwhelming results from weight loss drug trials, highlighting the significant scientific challenges in this emerging market [11].

Core Viewpoint - Viking Therapeutics experienced a significant decline in share price, dropping over 43% after disappointing mid-stage trial results for its weight-loss pill VK2735, reflecting intense competition in the pharmaceutical industry for oral weight-loss drugs [1][3]. Company Summary - Viking Therapeutics' shares fell approximately 43% to just below $24, marking the largest single-day decline since its IPO in May 2015 and a 69.5% decrease from its 52-week high of $81.73 set in October 2024 [3][4]. - The stock plunge resulted in about $1.8 billion in losses, reducing the company's market capitalization by more than one-third to $2.8 billion [4]. Product Performance - VK2735 demonstrated an average weight loss of 12.2% after 13 weeks, compared to a 1.3% loss with a placebo [4]. - However, 28% of patients discontinued the trial due to gastrointestinal side effects, including nausea and vomiting [5]. Competitive Landscape - VK2735's weight-loss results were lower than those of competitors, such as Eli Lilly's orforglipron, which achieved a 12.4% weight loss over 72 weeks, and Novo Nordisk's oral Wegovy, which helped patients lose 15% of their body weight [6]. - Eli Lilly's shares also fell over 14% following the release of orforglipron trial data, marking its largest single-day loss since 2000, while Novo Nordisk's shares rose more than 7% [7]. Industry Context - Viking Therapeutics is positioning itself in the growing weight-loss medication market, developing both oral and injectable alternatives [8]. - The oral version of Novo Nordisk's Wegovy is under FDA review, with a decision expected by late 2025, while other weight-loss pill trials, such as Pfizer's danuglipron, have been abandoned due to safety concerns [8].

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Datahttps://t.co/ox0riQ219o https://t.co/YObQIQHBdN ...

Shares of Viking Therapeutics fell more than 30% in premarket trading Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. The results could be a blow to Viking, which was once seen as a hot M&A target as pharmaceutical companies scramble to join the booming market for obesity and diabetes drugs. It could reinforce Eli Lilly and Novo Nordisk's dominance in the space, especially as they develop pills for weight loss that could enter the market years ahead o ...

Viking Therapeutics (VKTX) Conference Call Summary Company Overview - **Company**: Viking Therapeutics (VKTX) - **Date**: August 19, 2025 - **Key Speakers**: Brian Lyon (President and CEO), Maryann Mancini (COO), Karen Modesto (Executive Director, Clinical Development), Greg Zanti (CFO) Core Industry and Product Focus - **Industry**: Biotechnology, specifically focused on obesity treatment - **Product**: VK2735, a dual agonist of GLP-1 and GIP receptors Key Points and Arguments Phase II Study Results - Viking announced top-line results from the Phase II Venture oral dosing trial for VK2735, aimed at treating obesity [3][5] - The study achieved its primary and secondary endpoints, demonstrating statistically significant reductions in body weight [11] - Subjects receiving VK2735 showed weight loss up to **12.2%** from baseline and **10.9%** relative to placebo [12] - The treatment was reported as safe and well-tolerated, with most adverse events classified as mild or moderate [11][16] Weight Loss and Efficacy - VK2735 demonstrated a progressive weight loss trend throughout the 13-week treatment period, with no evidence of plateauing [12] - Up to **97%** of subjects achieved at least **5%** weight loss compared to **10%** for placebo, and **80%** achieved at least **10%** weight loss compared to **5%** for placebo [13] - The study included an exploratory arm assessing the transition from high daily doses to lower maintenance doses, showing effective weight retention [14] Safety and Tolerability - Adverse event rates were higher in VK2735 treated cohorts compared to placebo, primarily due to gastrointestinal (GI) events [16][17] - **11%** of VK2735 treated subjects discontinued the study early, compared to **5%** for placebo [16] - GI-related adverse events were most prevalent in the first week, with rates declining over time [18] Future Development Plans - Viking plans to initiate a Phase III registration program for VK2735, named the Vanquish studies, which will evaluate the drug in adults with obesity and those with type 2 diabetes [6][7] - The company is also developing an oral tablet formulation of VK2735, which could provide an alternative treatment option for patients [7][8] Market Positioning and Strategy - The company believes that the dual formulation (oral and subcutaneous) could mitigate safety challenges when transitioning patients between treatments [8] - Viking aims to explore the potential for lower maintenance doses based on the encouraging results from the maintenance dosing cohort [19] Questions and Answers Insights - Discussions highlighted the need for a slower titration rate in future studies to improve tolerability [22][56] - The company is considering the implications of dosing regimens, including the potential for less frequent dosing to enhance patient compliance [120] Other Important Considerations - The results from the exploratory maintenance dosing cohort provide a proof of concept for transitioning patients to low-dose maintenance therapy [19] - Viking's approach to addressing GI tolerability through optimized titration regimens is a key focus for upcoming studies [34][56] This summary encapsulates the critical insights from the Viking Therapeutics conference call, focusing on the company's advancements in obesity treatment through VK2735 and its strategic plans moving forward.